Patents by Inventor Junji Onoda
Junji Onoda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11643458Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.Type: GrantFiled: May 30, 2019Date of Patent: May 9, 2023Assignee: SHIONOGI & CO., LTD.Inventors: Tatsuya Takahashi, Mai Yoshikawa, Sosuke Yoneda, Junji Onoda, Etsuo Nakamura, Tsuguo Miyauchi, Toshiyuki Asaki, Erika Kasai
-
Publication number: 20220064312Abstract: Disclosed is a novel anti-CCR8 antibody. The antibody can be used for treating or preventing cancers or the like.Type: ApplicationFiled: December 27, 2019Publication date: March 3, 2022Applicants: Shionogi & Co., Ltd., Osaka UniversityInventors: Mai Yoshikawa, Tatsuya Takahashi, Junji Onoda, Sunao Imai, Etsuo Nakamura, Kentaro Furukawa, Tsuguo Miyauchi, Tetsuya Yoshida, Morio Nagira, Naganari Ohkura, Atsushi Tanaka, Shimon Sakaguchi, Hisashi Wada, Atsunari Kawashima
-
Publication number: 20210221876Abstract: Objective of the present invention is to provide a novel monoclonal antibody against Nav1.7. The present invention discloses a monoclonal antibody against Nav1.7 or its antibody fragment, having specific six CDRs (CDR1 to CDR3 of a heavy chain and CDR1 to CDR3 of a light chain) or specific heavy/light chain variable regions. The monoclonal antibody and the like can be used for treating or preventing pain, pruritus and so on.Type: ApplicationFiled: May 30, 2019Publication date: July 22, 2021Applicant: SHIONOGI & CO., LTD.Inventors: Tatsuya TAKAHASHI, Mai YOSHIKAWA, Sosuke YONEDA, Junji ONODA, Etsuo NAKAMURA, Tsuguo MIYAUCHI, Toshiyuki ASAKI, Erika KASAI
-
Patent number: 10745491Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: January 11, 2019Date of Patent: August 18, 2020Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20190211114Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: January 11, 2019Publication date: July 11, 2019Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 10239955Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: June 2, 2017Date of Patent: March 26, 2019Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Publication number: 20170275378Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: June 2, 2017Publication date: September 28, 2017Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 9701757Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: March 12, 2014Date of Patent: July 11, 2017Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi
-
Patent number: 9296825Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: GrantFiled: October 11, 2012Date of Patent: March 29, 2016Assignee: SHIONOGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Publication number: 20160009819Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: March 12, 2014Publication date: January 14, 2016Applicant: SHIONOGI & CO., LTD.Inventors: Shoichi NAITO, Junji ONODA, Tasuku TSUKAMOTO, Katsutoshi YAMADA, Shoji YAMANE, Yoshito NUMATA, Kazuhiko MAEKAWA, Tatsuya TAKAHASHI
-
Patent number: 9222947Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.Type: GrantFiled: February 1, 2013Date of Patent: December 29, 2015Assignee: SHIONOGI & CO., LTD.Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
-
Publication number: 20150111231Abstract: Provided are a monoclonal antibody capable of specifically recognizing a specific region of sAPP ? or a fragment of said antibody and an assay method and an assay kit using the same, in order to accurately assay sAPP? contained in a biological sample.Type: ApplicationFiled: February 1, 2013Publication date: April 23, 2015Inventors: Tatsuya Takahashi, Junji Onoda, Yasunobu Yoshida, Shoji Yamane, Kouhei Nishitomi, Hidekuni Yamakawa, Akira Yamauchi, Atsushi Morita, Isao Fukuda
-
Publication number: 20150025225Abstract: Provided is a monoclonal antibody or a fragment thereof that selectively inhibits enzyme activity of EL and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome.Type: ApplicationFiled: October 11, 2012Publication date: January 22, 2015Inventors: Shoichi Naito, Junji Onoda, Tasuku Tsukamoto, Katsutoshi Yamada, Shoji Yamane, Yoshito Numata, Kazuhiko Maekawa, Tatsuya Takahashi, Yasuhiko Sato
-
Patent number: 8722856Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: GrantFiled: October 28, 2009Date of Patent: May 13, 2014Assignees: National University Corporation Hokkaido University, Shionogi & Co., Ltd.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Patent number: 8536313Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: GrantFiled: July 8, 2008Date of Patent: September 17, 2013Assignee: Shionogi & Co., Ltd.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Publication number: 20120237948Abstract: The present invention provides a novel monoclonal antibody that is specific for a C-terminal neoepitope of a collagen fragment and has substantially equal binding affinity whether proline contained in the neoepitope is in a non-hydroxylated form or in a hydroxylated form, and an immunoassay, a measurement method, a kit and the like using the antibody. The antibody allows for quantification of a collagen fragment generated by digestion of a biological sample with a collagenase present in the sample, regardless of the presence or absence of a hydroxylated form of proline in the neoepitope.Type: ApplicationFiled: September 16, 2010Publication date: September 20, 2012Applicant: Shionogi & Co., Ltd.Inventors: Yoshito Numata, Akira Yamauchi, Junji Onoda, Shoji Yamane, Tomoko Maeda
-
Publication number: 20120040375Abstract: An object of the present invention is to provide an antibody which does not bind to a normal cell, and is specific for a cancer cell. The object was solved by the finding by the present inventors that an antibody obtained by immunizing an animal using a 2,3ST glycopeptide as an antigen unexpectedly recognizes a sugar chain specific for a cancer specifically and remarkably, and consequently, can recognize and kill a cancer cell expressing MUC1 having such a cancer cell-specific sugar chain. The present invention provides, for example, an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, in which specificity for a cancer-associated structure of MUC1 is 100-fold or more as compared with that for a normal tissue-associated structure of MUC1.Type: ApplicationFiled: October 28, 2009Publication date: February 16, 2012Applicants: SHIONOGI & CO., LTD.Inventors: Shin-Ichiro Nishimura, Hiroshi Hinou, Yoshito Numata, Junji Onoda, Shoichi Naito, Naoki Ohyabu
-
Publication number: 20100330092Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: ApplicationFiled: July 8, 2008Publication date: December 30, 2010Applicant: SHIONLGI & CO., LTD.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Publication number: 20090298196Abstract: The present invention is intended to provide a method of rapidly, simply and accurately measuring a recombinant protein. As means for resolution, the protein quantity is measured by causing the expression of a fusion protein with the target protein and epitope tags containing two types of epitopes, bringing them into contact with detection antibodies which specifically recognize each epitope, and detecting a phenomenon caused by both detection antibodies coming close to each other.Type: ApplicationFiled: January 26, 2006Publication date: December 3, 2009Inventors: Ken-ichiro Uwabe, Koji Enomoto, Junji Onoda, Yoshito Numata, Hiroshi Takemoto